Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-Her2-affibody PET/CT Imaging of Her2 Expression
NCT06289517Recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-ABY-025 in breast cancer, sponsored by Peking University First Hospital. Primary endpoint: The diagnostic efficacy of 68Ga-Her2-affibody PET/CT in the evaluation of breast cancer at 1 year. Started May 2024; status: recruiting.
02
Drugs
68Ga-ABY-025
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06289517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289517.